CTOs on the Move


 
Kurion creates technological solutions to minimize and stabilize nuclear and hazardous waste for safe, secure and permanent disposal.  Kurion’s suite of waste separation, stabilization and robotic technologies are complemented by engineering and environmental services that together provide an execution platform to service the world’s largest nuclear and hazardous waste sites. Backed by venture capital firms Lux Capital, Firelake Capital and Acadia Woods Partners, the Kurion executive team employs a collective 150 years of industry experience managing nuclear and hazardous waste for commercial and government sites worldwide. Kurion is based in Irvine, Calif., and operates a technology development center at its radioactive materials licensed ...
  • Number of Employees: 250-1000
  • Annual Revenue: > $1 Billion
  • www.kurion.com
  • 2020 Main St. Suite 300
    Irvine, CA USA 92614
  • Phone: 949.398.6350

Executives

Name Title Contact Details

Similar Companies

BioMedix

Previously Mr. Lerner has served as Vice President of Engineering and Technology for both Image Sensing Systems, Inc. and Telex Communications, Inc.

Blue Sky Biotech Inc

Blue Sky Biotech Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celerion Inc

Celerion Inc is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MiMedx

MiMedx is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, six completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts. MiMedx has supplied over 1 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Stallergenes

Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.